Over a third of low-grade (1-2) toxicities are considered "life-changing" by patients. CTCAE grades were designed for physician decision-making (e.g., is it safe to give the next dose?), not to capture the true, long-term impact on a patient's quality of life.

Pre-approval clinical trials, run by drug makers, reported a sub-2% discontinuation rate due to side effects. Post-market observational data reveals a starkly different reality: approximately 10% of patients stop taking statins due to adverse effects like muscle pain.

The study utilized "interruption-free survival" as a primary endpoint, a pragmatic measure derived from real-world data. This serves as a valuable surrogate for treatment toxicity, as clinicians typically pause treatment in response to adverse events, providing a quantifiable measure of a drug's real-world tolerability.

Current Quality of Life (QoL) assessments in cancer trials fail to capture severe, long-term toxicities. They are designed for short-term effects and data collection often ceases after a patient experiences a life-changing adverse event, thus painting an inaccurately rosy picture of a drug's tolerability.

In clinical trials, patients "vote with their feet." High rates of discontinuing an optional (adjuvant) phase of treatment provide a clearer, real-world signal of toxicity and their personal risk-benefit analysis than formal Quality of Life surveys. Their actions speak louder than their written responses.

Multiple perioperative studies like Ambassador and Ramparts show no significant quality of life difference between active drugs with known side effects and placebo. This recurring finding suggests that current QoL measurement tools are not sensitive enough to capture the real, long-term toxicities patients experience.

Quality of Life data collected only during clinic visits fails to capture the patient's experience during their "off" weeks, which is often when they feel the worst. Accurate QoL assessment requires remote, high-frequency data collection to get a true picture of the treatment burden over time.

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.

Current quality of life assessments in trials are inadequate for immunotherapy. They fail to track life-altering toxicities that persist long after patients stop treatment, as data collection often ceases. This systemic flaw dilutes the true patient burden and calls for new methods to measure long-term, post-treatment quality of life.